Central Virginia Health Services, New Canton, VA 23123.
Virginia Tech Carilion School of Medicine, Roanoke, VA 24016.
J Immunol. 2020 Jul 1;205(1):12-19. doi: 10.4049/jimmunol.2000413. Epub 2020 May 18.
The 2019 coronavirus disease (COVID-19) pandemic caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has created an unprecedented global crisis for the infrastructure sectors, including economic, political, healthcare, education, and research systems. Although over 90% of infected individuals are asymptomatic or manifest noncritical symptoms and will recover from the infection, those individuals presenting with critical symptoms are in urgent need of effective treatment options. Emerging data related to mechanism of severity and potential therapies for patients presenting with severe symptoms are scattered and therefore require a comprehensive analysis to focus research on developing effective therapeutics. A critical literature review suggests that the severity of SARS-CoV-2 infection is associated with dysregulation of inflammatory immune responses, which in turn inhibits the development of protective immunity to the infection. Therefore, the use of therapeutics that modulate inflammation without compromising the adaptive immune response could be the most effective therapeutic strategy.
由病毒严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）大流行，给基础设施部门造成了前所未有的全球危机，包括经济、政治、医疗保健、教育和研究系统。尽管超过 90%的感染者无症状或表现出非关键性症状，并将从感染中恢复，但那些表现出严重症状的患者急需有效的治疗选择。与严重症状患者的发病机制和潜在治疗方法相关的新兴数据较为分散，因此需要进行综合分析，以便将研究重点放在开发有效的治疗方法上。一项关键性文献综述表明，SARS-CoV-2 感染的严重程度与炎症免疫反应失调有关，而炎症免疫反应失调又会抑制对感染产生保护性免疫。因此，使用调节炎症而不损害适应性免疫反应的治疗方法可能是最有效的治疗策略。
